trending Market Intelligence /marketintelligence/en/news-insights/trending/b97N2AQQv0GLkdoGltviGw2 content esgSubNav
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us
In This List

Gemphire stock falls as cholesterol drug disappoints in phase 2b trial

Blog

Needham & Company is Now Available in the S&P Global Market Intelligence Aftermarket Research Collection

Blog

Banking Essentials Newsletter - February Edition

Blog

Message in a (Word)Cloud

Six trends shaping the industries and sectors we cover in 2021


Gemphire stock falls as cholesterol drug disappoints in phase 2b trial

Gemphire Therapeutics Inc.'s cholesterol drug, gemcabene, met its primary endpoint in a phase 2b study but failed to match results observed in previous trials.

Under the Royal-1 trial, gemcabene was seen to significantly decrease low-density lipoprotein cholesterol, or LDL-C, in hypercholesterolemic patients: 17.2% versus 5.5% for placebo, but still lower than what was observed previously.

The trial enrolled 56 females and 49 males with a mean age of 61.

Gemphire Therapeutics shares were down nearly 47% to $9.93 at market close on Aug. 7.